Estrella Biopharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2022-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.estrellabio.com
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Phase 1
Recruiting
- Conditions
- Lymphoma, Non-HodgkinsLymphomas Non-Hodgkin's B-CellLarge B-Cell LymphomaRelapsed Non-Hodgkin LymphomaB-Cell Non-Hodgkin's Lymphoma (NHL)Lymphoma, Non-HodgkinCNS LymphomaNon-Hodgkin LymphomaLymphomaRefractory B-Cell Non-Hodgkin Lymphoma
- Interventions
- Biological: EB103
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Estrella Biopharma, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT06343311
- Locations
- 🇺🇸
University of California, Davis, Sacramento, California, United States
© Copyright 2025. All Rights Reserved by MedPath